Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...
Prif Awduron: | Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
2008
|
Eitemau Tebyg
-
The role of somatostatin analogues in the treatment of neuroendocrine tumours.
gan: Grozinsky-Glasberg, S, et al.
Cyhoeddwyd: (2008) -
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
gan: Kaltsas, G, et al.
Cyhoeddwyd: (2005) -
Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
gan: King, C, et al.
Cyhoeddwyd: (1993) -
Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
gan: Gupta, P, et al.
Cyhoeddwyd: (2014) -
Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
gan: Ur, E, et al.
Cyhoeddwyd: (1993)